Dexamethasone

Treatment for COVID-19

Typical Dosage: 6 mg orally or IV once daily

Effectiveness
80%
Safety Score
50%
Clinical Trials
109
Participants
100K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
6 mg orally or IV once daily
Time to Effect
2-3 days
Treatment Duration
7-10 days
Evidence Quality
HIGH
Number Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$50
Side Effect Mgmt:$100
Total Annual:$170
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$1,757/QALY
QALYs Gained
0.046
Outcome-Based Costs
Cost per Responder
$485.71
Comparison vs Supportive care
Cost Difference
$-500/year
Less expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Dexamethasone Outcomes

for COVID-19

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+35%
Common Side Effects
Hyperglycemia
+15%
Insomnia
+10%
Mood changes
+7%
Fluid retention
+8%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
11 completed trials for Dexamethasone in COVID-19

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

NCT04707534COMPLETEDPHASE4
View Study
110 participants
INTERVENTIONAL
Oklahoma City, United States
Started: Jan 21, 2021

Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

NCT04513184COMPLETEDPHASE2
View Study
66 participants
INTERVENTIONAL
Mexico City, Mexico +2 more
Started: Nov 5, 2021

Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia

NCT04509973COMPLETEDPHASE3
View Study
1K participants
INTERVENTIONAL
Aalborg, Denmark +52 more
Started: Aug 27, 2020

Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19

NCT04663555COMPLETEDPHASE4
View Study
235 participants
INTERVENTIONAL
Brno, Czechia
Started: Feb 2, 2021

Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia

NCT04329650COMPLETEDPHASE2
View Study
163 participants
INTERVENTIONAL
Badalona, Spain +3 more
Started: Apr 15, 2020

Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19

NCT04726098COMPLETEDPHASE4
View Study
198 participants
INTERVENTIONAL
Santiago de Compostela, Spain
Started: Jan 15, 2021

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168COMPLETEDPHASE3
View Study
1.01K participants
INTERVENTIONAL
Birmingham, United States +71 more
Started: Dec 2, 2020

Impact of Steroids on Inflammatory Response in Covid-19

NCT04909918COMPLETEDPHASE3
View Study
60 participants
INTERVENTIONAL
Asyut, Egypt
Started: May 28, 2021

A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects

NCT05004753COMPLETEDPHASE4
View Study
120 participants
INTERVENTIONAL
Srikakulam, India +2 more
Started: Sep 30, 2020

Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

NCT04890626COMPLETEDPHASE3
View Study
356 participants
INTERVENTIONAL
Madrid, Spain
Started: Apr 4, 2020

Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease

NCT04603729COMPLETEDPHASE3
View Study
100 participants
INTERVENTIONAL
Lahore, Pakistan
Started: May 30, 2020
Showing 20 of 109 total trials